Teleflex's (TFX) "Overweight" Rating Reiterated at Piper Sandler

Key Points

• Piper Sandler reaffirmed its “Overweight” rating on Teleflex and raised its price target to $169 from $160, implying approximately 24.8% upside from the reported share price.
• Teleflex reported second-quarter revenue of $570.3 million and adjusted EPS of $1.76, beating analyst estimates of $559.6 million and $1.28, respectively. Management issued fiscal 2026 adjusted EPS guidance of $6.90–$7.20, above the $6.70 consensus estimate.
• Despite the earnings beat, underlying trends were mixed: adjusted EPS declined from $3.73 a year earlier and constant-currency pro forma revenue growth was 4.7%. Analysts’ average rating remains “Hold,” with a consensus price target of $149.80.

Teleflex (NYSE:TFX - Get Free Report)'s stock had its "overweight" rating reaffirmed by research analysts at Piper Sandler in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $169.00 target price on the medical technology company's stock, up from their previous target price of $160.00. Piper Sandler's target price points to a potential upside of 24.81% from the stock's current price.

Other equities research analysts also recently issued research reports about the stock. Wall Street Zen downgraded shares of Teleflex from a "hold" rating to a "sell" rating in a research note on Saturday, August 1st. Mizuho raised their price objective on shares of Teleflex from $140.00 to $145.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 15th. Wells Fargo & Company upped their target price on Teleflex from $130.00 to $138.00 and gave the company an "equal weight" rating in a research note on Friday, May 8th. Zacks Research raised Teleflex from a "strong sell" rating to a "hold" rating in a research report on Tuesday, April 28th. Finally, Raymond James Financial reissued an "outperform" rating and set a $150.00 target price on shares of Teleflex in a research note on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Teleflex has an average rating of "Hold" and a consensus target price of $149.80.

Teleflex Price Performance

Shares of Teleflex stock traded down $3.48 during trading hours on Friday, reaching $135.41. The company's stock had a trading volume of 207,256 shares, compared to its average volume of 796,840. The firm has a 50 day moving average price of $131.61 and a 200-day moving average price of $122.46. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.55 and a quick ratio of 2.03. The stock has a market cap of $5.99 billion, a P/E ratio of -5.93, a P/E/G ratio of 1.02 and a beta of 0.81. Teleflex has a one year low of $100.18 and a one year high of $145.00.

Teleflex (NYSE:TFX - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The medical technology company reported $1.76 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.48. The company had revenue of $570.33 million for the quarter, compared to analysts' expectations of $559.59 million. Teleflex had a positive return on equity of 13.29% and a negative net margin of 35.88%.The firm's revenue for the quarter was up 28.9% on a year-over-year basis. During the same period in the previous year, the firm posted $3.73 earnings per share. Teleflex has set its FY 2026 guidance at 6.900-7.200 EPS. On average, analysts predict that Teleflex will post 6.7 EPS for the current year.

Institutional Trading of Teleflex

A number of institutional investors have recently modified their holdings of the company. BlackRock Inc. bought a new position in shares of Teleflex during the 2nd quarter worth approximately $688,537,000. Deutsche Bank AG purchased a new position in Teleflex during the 2nd quarter worth $6,106,000. Rice Hall James & Associates LLC acquired a new position in Teleflex during the 2nd quarter valued at about $578,000. Trust Co. of Vermont acquired a new stake in Teleflex in the second quarter worth about $57,000. Finally, Diamond Hill Capital Management LLC Investment Advisor acquired a new position in shares of Teleflex during the second quarter valued at about $39,467,000. 95.62% of the stock is currently owned by institutional investors.

Key Stories Impacting Teleflex

Here are the key news stories impacting Teleflex this week:

• Positive Sentiment: Teleflex reported second-quarter revenue of $570.3 million, up 28.9% year over year and above the $559.6 million consensus estimate. Adjusted EPS was $1.76, beating expectations of $1.28. Teleflex Surpasses Q2 Earnings and Revenue Estimates
• Positive Sentiment: Management provided fiscal 2026 adjusted EPS guidance of $6.90 to $7.20, above the analyst consensus of $6.70. Full-year revenue guidance of approximately $2.3 billion was broadly in line with expectations, suggesting earnings execution remains a strength. Teleflex Reports Second Quarter Results and Outlook
• Neutral Sentiment: Teleflex declared a quarterly dividend of $0.34 per share, payable September 30 to shareholders of record August 14. The dividend represents an annualized payout of $1.36 per share and an approximately 1% yield.
• Negative Sentiment: GAAP diluted EPS from continuing operations fell to $0.96 from $1.54 in the prior-year quarter, while adjusted EPS declined from $3.73 a year earlier despite the headline beat. This weaker year-over-year earnings trend may be weighing on investor sentiment. Teleflex Q2 2026 Earnings Call Transcript
• Negative Sentiment: Revenue growth was only 4.7% on a pro forma adjusted constant-currency basis, considerably below the reported 28.9% increase. With revenue guidance merely matching consensus, investors may be focused on the pace of underlying growth rather than the acquisition- or accounting-related headline increase.

Teleflex Company Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company's offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source